Several studies at the 2026 ASCO Annual Meeting examined how GLP-1 medications and weight loss relate to breast cancer risk. These are associations, not proof of cause.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
She argues the FDA held its remand decision until after oral arguments so the court wouldn't have it in hand. Few other details are given.
The UK biotech, launched with $410 million, ended the switch study after enrolling just eight of 120 planned patients, citing market evolution.
Loading…